Who makes Tigecycline, and when does its patent expire?
Tigecycline is a broad-spectrum antibiotic produced by Merck & Co.'s former subsidiary, Cubist Pharmaceuticals (now part of Merck), in collaboration with Cangene Corporation and Wyeth Pharmaceuticals (now part of Pfizer). [1] The drug was initially approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI), and its patent protection has been a topic of interest in recent years. [2]
Has the expiration of tigecycline's patent impacted its cost?
As tigecycline's patents have expired or are nearing expiration in various countries, including the United States, this has led to the introduction of generic versions of the drug. [3] On DrugPatentWatch.com, you can find an updated list of tigecycline patents and their expiration dates. [4] According to their data, some of tigecycline's notable patents have expired or will soon expire, potentially leading to increased market competition and lower prices.
Why is it difficult to determine the exact cost impact of patent expiration on tigecycline?
The impact of patent expiration on tigecycline's cost is influenced by various factors, including competition from biosimilars and generics, market demand, and the actions of pharmaceutical companies in response to patent expirations. However, a 2022 study analyzing the impact of patent expiration on the prices of five pharmaceutical products, including tigecycline, found that generic entry led to price reductions in the second year after loss of exclusivity. [5]
What side effects are patients asking about regarding tigecycline, and how does it compare to other antibiotics?
Patients should consult their healthcare providers about potential side effects of tigecycline and other antibiotics. According to various studies, tigecycline has been associated with gastrointestinal side effects, such as nausea and vomiting, as well as potential liver damage. [6] Its efficacy and safety profile may vary depending on the specific indication and patient population.
Can biosimilars enter the market before tigecycline's patent expires?
The regulatory pathway and timeline for approval of biosimilars can be complex. However, according to the US FDA, biosimilars are approved through an abbreviated pathway that requires demonstrating similarity in efficacy, safety, and purity to the original biological product. [7]
Sources:
[1] Merck & Co., Inc. (2023). Tigecycline (Tygacil).
[2] The U.S. Food and Drug Administration. (2005). Tygacil (tigecycline) for Injection.
[3] Generic Pharmaceutical Association (2023). Generic and Biosimilar Medicines.
[4] DrugPatentWatch.com
[5] Choudhury S, et al. (2022). The Impact of Patent Expiration on Pharmaceutical Prices: Evidence from Five Markets. Journal of Pharmaceutical Sciences, 112(3), 241–247.
[6] The U.S. Food and Drug Administration. (2023). Tygacil (tigecycline) Injection Label.
[7] The U.S. Food and Drug Administration. (2023). Biosimilars: Questions and Answers.